Full-year results to be published on 26 September from consumer goods firm PZ Cussons (PZC) come hot on the heels of the company's announcement that it plans to take full control of its Nigerian business.This decision may come under some scrutiny as the impact of the devaluation of the Nigerian naira could well mar the upcoming numbers. Volatility in the currency and the country itself has been a

Wednesday 27 September

Neil Woodford-backed Circassia (CIR) has decided to make no further investments in its allergy programmes after its Phase IIb field study failed to meet its primary endpoint. Top-line results from the speciality pharmaceutical firm's dust mite allergy immunotherapy study revealed the treatment did not show a significant effect when compared to a placebo. The market is taking the setback relatively

Management at Circassia (CIR) plans to transition from allergy-focused biotech into a speciality pharmaceutical after its main cat allergy treatment failed during clinical trials in June.A focus on developing respiratory generics and selling other company's treatments through its sales channels is the direction that Neil Woodford-backed business is now taking.After a placebo outperformed its lead